Investor Relations
Every disease
has a sequence.
Seek Labs is building the disease-response platform.
One genomic intelligence layer powers two product engines: Sequence Ablation Therapeutics and point-of-need molecular diagnostics, both engineered from the same conserved-sequence backbone. One intelligence architecture, two product categories, hundreds of diseases in scope.
Why Now
The last generation answered one disease at a time. The next generation is programmable.
-
01
Pathogen genomes are now read in hours, not years. AI can scan them at scale and pinpoint the conserved regions a virus cannot mutate without breaking itself — turning sequence into a target the same day it appears.
-
02
CRISPR has matured from a gene-editing tool into a programmable execution layer. The chassis stays the same; only the guide RNA changes. A new disease becomes a new program, not a new drug.
-
03
Computation closed the gap with chemistry. Modern sequence-design models read millions of pathogen and host genomes, predict which conserved regions are safe to hit, and rank candidate guides and probes before any wet-lab work begins — turning months of screening into hours at the keyboard.
-
04
SeekIt is being developed as an instrument-free, single-use molecular diagnostic for the point of need. Sealed cartridges. No thermocycler, no lab. As patient demand shifts toward at-home and near-patient testing, Seek Labs is building a platform designed to meet that need. SeekIt is investigational and not cleared by FDA.
The Opportunity
An unusual convergence.
A company built for it.
Why now
Molecular medicine has reached an inflection point.
Every disease has a sequence, and that sequence contains vulnerabilities. AI now decodes entire disease families and pinpoints conserved regions in hours. CRISPR is programmable. What’s missing are the platforms that turn this convergence into detection and treatment at the speed of disease. That’s what Seek Labs is building.
Why us
One AI brain. Two platforms.
BioSeeker is AI-powered genomic discovery. It reads thousands of sequences to map the conserved regions a pathogen cannot mutate without losing essential function. From that map, it designs the molecular tools both platforms need: CRISPR guide RNAs for therapeutics, primer and probe sets for diagnostics. One brain. Two platforms.
Not a single-bet drug
When the next pathogen emerges, the platform is designed to respond without starting from zero.
25/25 WHO priority viral families mapped. 145+ infectious diseases mapped. When the next pathogen emerges, Seek Labs is not at day zero. In a preclinical swine challenge study, our CRISPR-based therapeutic candidate increased survival relative to untreated controls in African Swine Fever Virus. Additional studies are needed. Designed to be disease-agnostic, rapidly reprogrammable, and AI-guided. Designs against multiple priority pathogen families have already been generated.
Platform thesis
A platform
built on conserved biology.
A new category, not a new molecule. Sequence Ablation Therapeutics is a new modality. The same genomic logic that designs a therapeutic also designs a diagnostic, so every new program builds on the platform rather than starting from scratch.
A compounding platform. BioSeeker compounds in value. Every new pathogen mapped can expand the platform’s design reach without requiring a proportional expansion of the operating model. Because we design against conserved sequences a pathogen cannot mutate without losing fitness, the platform is designed to retain effectiveness as pathogens evolve.
Multiple paths forward, federal-anchored. Three programs advance in parallel from a single platform: licensable diagnostics with established field-validation partners, programmable therapeutics with USDA non-dilutive funding in hand, and biodefense engagement across BARDA RRPV, BioMaP, MCDC, MTEC, DARPA Connect, and NAVALX Vulcan. Three program tracks share one underlying platform.
BioSeeker™
AI genomic engine. 25/25 WHO priority viral families mapped.
SAT
Sequence Ablation Therapeutics. Programmable. Multi-site. Conserved-region targeting.
PTAP™
Programmable Target Ablation Platform. The therapeutic execution layer.
SeekIt™
Instrument-free, single-use diagnostic for the point of need. Investigational; not cleared by FDA.
ANINA™
Seek Amplification
Isothermal amplification chemistry. Field-ready, no thermocycler.
VELOX™
Seek Extraction
Sample preparation and extraction across tissue, blood, saliva, urine, swab.
Federal
Biodefense innovation pathways engaged.
BARDA RRPV · BioMaP · MCDC · MTEC · DARPA Connect · NAVALX Vulcan
Consortium membership does not imply endorsement of Seek Labs or its products by any U.S. government agency.
$2M
USDA grant awarded (2026)
Partners & Networks
Inside the networks that matter.
Seek Labs is a member of the federal, defense, and global research consortia that drive medical countermeasure development, biomanufacturing readiness, and outbreak response — the access lanes we are building on.
- BARDA RRPV Member of BARDA’s Rapid Response Partnership Vehicle, a dynamic network supporting accelerated countermeasure development.
- BioMaP Member of the BARDA-aligned Biopharmaceutical Manufacturing Preparedness Consortium, advancing rapid, scalable manufacturing for medical countermeasures.
- MCDC Member of the DoD’s Medical CBRN Defense Consortium, an alliance enhancing the mission effectiveness of military personnel.
- MTEC Member of the DoD’s OTA, Medical Technology Enterprise Consortium, advancing the rapid deployment of innovative medical technologies.
- DARPA Connect Member of DARPACONNECT, a gateway to defense opportunities and breakthrough technology development.
- NAVALX Vulcan Member of NAVALX Vulcan under the Navy’s Rapid Capabilities Office to accelerate the delivery of innovative solutions to emerging challenges.
- CURE Member of Cure, a premier healthcare innovation ecosystem helping innovators from concept to commercialization.
- GARA Member of the Global African Swine Fever Research Alliance, a coordinated global research alliance enabling the progressive control and eradication of ASF.
Publications
The science behind the platform. Peer-reviewed and editorial publications from the Seek Labs team.
-
Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats
Read publication →: Seek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral ThreatsSeek Labs Publishes Editorial Review on the Future of CRISPR Antivirals in an Era of AI-Designed Viral Threats December 8, 2025 Read the full open-access review in Viruses Seek Labs today announced the publication of a new editorial review in Viruses (MDPI), authored by Alison O’Mahony, Senior VP of Research, and Douglas P. Gladue, VP…
-
Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever
Read publication →: Seek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine FeverSeek Labs Publishes First Peer-Reviewed Paper Demonstrating A CRISPR-Based Therapeutic Is Effective Against African Swine Fever November 17, 2025 SALT LAKE CITY, UT (Business Wire) – Seek Labs, a biotechnology company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced the publication of a peer-reviewed paper in Viruses (MDPI),…
Governance
Board of Directors
Board includes members with scientific, operational, governance, and capital-markets experience.
Bill Stoddart, MA
Board Chair, Co-Founder 45 North Partners
Randy Rasmussen, PhD
Co-Founder, BioFire Diagnostics
Cindy Dunkle
Biotech executive with leadership experience at Genentech and Denali Therapeutics.
Michael Paul, PhD
CEO, Lineagen, MARAbio
Keith Marmer, MBA, DPT
Fmr. Chief Innovation Officer, University of Utah
Pete Koson, MBA, CMA
Founder, Ninety South Consulting CFO Services
Current Investors
Access your portfolio, cap table, and documents through our Pulley portal.
If you are an existing Seek Labs investor, your equity details, documents, and cap table are available in Pulley. Log in below to access your account.
Log in to Pulley